There is no widely available cure for HIV/AIDS. A handful of people have been cured through highly specialized stem cell transplants, but that procedure is far too risky and rare to serve as a general solution. What does exist is treatment so effective that people with HIV can now live nearly as long as everyone else, and researchers are pursuing several promising strategies that could eventually lead to a true cure.
Why HIV Is So Hard to Cure
The core problem is that HIV doesn’t just float around in the bloodstream. It inserts its genetic code directly into the DNA of certain immune cells, specifically a type of long-lived memory cell that the body keeps around for years or even decades. These infected cells sit quietly, not producing virus, essentially invisible to both the immune system and medications. This hidden stockpile is called the latent reservoir.
Antiretroviral therapy (ART) works by stopping the virus from making new copies of itself. It does this extraordinarily well. But it cannot touch the dormant viral DNA already woven into those memory cells. Those cells have a half-life of 8 to 15 years and can also duplicate themselves, replenishing the reservoir over time. If someone stops taking ART, the virus reactivates from these cells and rebounds within weeks. Research published in The Journal of Infectious Diseases confirmed that the reservoir’s stability hasn’t changed over more than a decade of observation, regardless of which drug regimen a person takes. Without a way to specifically target that reservoir, the virus persists for life.
The People Who Have Been Cured
A small number of individuals, starting with Timothy Ray Brown (known as “the Berlin patient”) in 2008, have been cured of HIV. All of them had both HIV and a life-threatening blood cancer. Their treatment involved destroying their existing immune system and replacing it with donor stem cells carrying a rare genetic trait: two copies of a mutation called CCR5-delta32. People born with this mutation have immune cells that lack the surface receptor HIV typically uses to break in. After transplant, the patients’ new immune systems were essentially HIV-resistant, and the virus never came back.
Several more patients, including those treated in London and Düsseldorf, have since replicated this outcome. In these cases, analysis showed that the original host immune cells were completely replaced by donor cells carrying the protective mutation. But stem cell transplants carry a significant risk of death, require a matched donor with this uncommon genetic variant (found in roughly 1% of people of European descent and rare in other populations), and involve months of grueling recovery. No doctor would recommend this procedure for someone whose HIV is well controlled by medication.
How Treatment Has Changed the Picture
While a cure remains elusive, modern treatment has transformed HIV from a fatal diagnosis into a manageable chronic condition. A large collaborative analysis of European and North American cohorts, published in The Lancet, found that a 40-year-old woman who started ART after 2015 could expect to live an additional 39 years, compared to about 46 years for women in the general population. That gap continues to narrow with newer, better-tolerated medications.
Treatment also eliminates the risk of transmission. When ART suppresses the virus to undetectable levels in the blood, a person cannot pass HIV to sexual partners. This principle, known as Undetectable equals Untransmittable (U=U), is supported by studies involving thousands of couples where zero transmissions occurred when the HIV-positive partner maintained an undetectable viral load. For many people living with HIV today, daily medication means a normal lifespan and no risk of infecting others.
Strategies Researchers Are Testing
Scientists are working on two broad types of cure. A sterilizing cure would eliminate every trace of HIV from the body. A functional cure (also called sustained remission) would leave some virus behind but train the immune system to keep it permanently suppressed without medication. Most researchers consider the functional cure a more realistic near-term goal.
Flushing Out the Reservoir
The “shock and kill” approach tries to force dormant HIV out of hiding. Drugs called latency-reversing agents wake up the sleeping infected cells, causing them to start producing viral proteins. Once exposed, those cells can theoretically be recognized and destroyed by the immune system or targeted therapies. Early trials using a drug called vorinostat demonstrated that it could disrupt HIV latency in people on ART. The challenge has been that reactivation is inconsistent, not all reservoir cells wake up at once, and the immune system often isn’t strong enough on its own to finish the job.
The opposite strategy, “block and lock,” aims to silence the virus so deeply that it can never reactivate, even without ART. Researchers are developing compounds that target a key viral protein responsible for switching on HIV gene expression. If the virus can be locked into permanent dormancy, the reservoir becomes irrelevant. This approach is still in earlier stages of development but represents an appealing path to functional cure.
Gene Editing With CRISPR
Perhaps the most dramatic approach involves using gene-editing technology to cut HIV’s DNA directly out of infected cells. Excision BioTherapeutics developed a therapy called EBT-101 that uses CRISPR to target and snip out integrated HIV sequences. The FDA authorized the first clinical trial of this technology in humans in 2022. Preclinical work in primates showed the therapy reached tissues throughout the body, edited viral DNA in all major reservoir sites, and produced no detectable off-target effects or toxicity at any dose tested. Human trial results are still pending, but the safety profile in animals was encouraging.
Vaccines and Antibody Therapy
Therapeutic vaccines (designed to treat, not prevent, infection) aim to train the immune system to control HIV without medication. A Phase 1 trial run by the International AIDS Vaccine Initiative tested an immunogen designed to stimulate production of a specific class of powerful antibodies. In that trial, 97% of recipients developed the precursor immune cells needed to generate those antibodies. Follow-up trials are now testing whether boosting with additional immunogens can guide those cells to produce fully mature, virus-neutralizing antibodies. Moderna and IAVI have also launched a Phase 1 trial using mRNA vaccine technology adapted from COVID-19 platforms, with early data showing strong immune responses in over 90% of participants.
Meanwhile, broadly neutralizing antibodies (bNAbs) are being tested as a form of passive immunotherapy. These lab-made antibodies can neutralize a wide range of HIV strains. New clinical trials are combining two or three bNAbs that target different parts of the virus, with the goal of covering over 95% of global HIV strains. Whether periodic antibody infusions can replace daily pills and keep the virus suppressed long-term is still being studied.
The Cost and Access Problem
Even if a cure emerges from the lab, getting it to the roughly 39 million people living with HIV worldwide is a separate challenge. Gene therapies approved for other diseases currently cost between $2.8 million and $4.25 million per patient, a figure that exceeds the entire annual health budget of many low- and middle-income countries where HIV is most prevalent. One-time gene therapies for HIV would likely fall in a similar range, at least initially.
Researchers are working to bring costs down. Optimized manufacturing techniques for the viral vectors used to deliver gene therapies could reduce production costs by up to 50%. Smaller, more portable CRISPR platforms and automated manufacturing systems are also in development. But closing the gap between a breakthrough in a research hospital and a treatment available at a clinic in sub-Saharan Africa will require not just scientific innovation but new models for pricing and distribution. For now, expanding access to existing ART, which costs as little as a few hundred dollars per year in generic form, remains the most impactful intervention for most people living with HIV.